How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC With Lutetium 177Lu PSMA RLT (RECIPROCAL)
Description:
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard way this medication is given.
Sponsor:
Alliance for Clinical Trials in Oncology
Contacts:
Shiva Baghaie, MPHguprotocols@alliancenctn.org
773-702-9171
Government Study Link:
NCT07200830 - Click here to see study onClinicalTrials.gov
177Lu-PSMA-617
Isotope(s):
Target(s):
- PSMA
Ligand: Small Molecules
Chelator: DOTA
Linker: 2-naphthyl-L-alanine (Nal) and tranexamic acid (TXA)
